Even with decades of development of pharma knowledge, and a complex regulatory system, things still blow up badly (e.g., Vioxx). And the pharma companies usually end up paying through the nose in liability, too. Here, we have a much weaker body of built-up knowledge and much weaker ex ante regulation.
Even with decades of development of pharma knowledge, and a complex regulatory system, things still blow up badly (e.g., Vioxx). And the pharma companies usually end up paying through the nose in liability, too. Here, we have a much weaker body of built-up knowledge and much weaker ex ante regulation.